{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 29,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Highlights clinical success in patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/12",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "500ae6b4-611b-4fa6-94a0-aba4bf303326",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "list",
      "text": "All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0984a649-f191-4335-8acd-4e0db7e1a307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.79
      },
      "kind": "list",
      "text": "Renal toxicity reversed and renal function returned to baseline after switching to MAT2203.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cbf6f61-07b7-407f-808e-2eaf02613fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "list",
      "text": "20 patients with no other treatment options have enrolled to receive or have completed treatment with MAT2203. Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nationwide Children’s Hospital, Vanderbilt University Medical Center, Memorial Sloan Kettering, University of California, San Diego School of Medicine, Children’s Hospital of Philadelphia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92784843-36ae-4868-a5de-3cdfe01cbf48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.57
      },
      "kind": "list",
      "text": "Patients were switched to treatment with IV Amphotericin B with clinical response but unable to tolerate treatment due to renal toxicity. All patients hospitalized to monitor/manage renal safety and most received IV electrolyte supplementation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab223578-2c4e-402b-9818-a2ee1a3e18b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Following oral MAT2203 initiation, patients were discharged to continue treatment at home.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1e5eede-04fd-4f32-9ecc-1e411a44704e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.5
      },
      "kind": "list",
      "text": "Patients were not responding/resistant to, or unable to receive, azole therapy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10a3ef9-af0b-4533-8da1-6af0517ffdee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "MAT2203 Expanded Access/Compassionate Use Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11a84055-5d9d-485c-b258-1cd4099122d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "66c87a9f-58bc-4bac-bcf4-34398f54c672",
      "evidence": "list/bullet: 20 patients with no other treatment options have enrolled to receive or have completed treatment with MAT2203. Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Natio",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "56364061-eb35-4da2-9296-61758579e6b7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Clinical validation and results of EnACT are presented",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "152bbf1c-1860-4dec-b978-15c2f9ed0c98",
      "evidence": "The high unmet medical need in IA and the growing threat of IFIs are highlighted",
      "position": 0,
      "objective": "What is the cost of not addressing the growing threat of IFIs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}